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Summary
Introduction:  Ameloblastic  ﬁbrosarcoma  (AFS)  is  a  rare  malignant  odontogenic  tumor.  It  can
arise de  novo,  however  one-third  of  cases  may  arise  from  a  recurrent  ameloblastic  ﬁbroma,  in
which case  they  appear  to  present  at  an  older  age.
Case report:  A  16-year-old  female  presented  with  one  month  history  of  right  mandibular  mass.
Computerized  tomography  (CT)  scan  showed  a  large  destructive  mass.  A  biopsy  of  the  mass
was performed.  Histologically,  it  consisted  of  a  mixed  epithelial-mesenchymal  odontogenic
neoplasm  composed  of  benign  islands  of  well-differentiated  ameloblastic  epithelium  within  a
malignant  ﬁbrous  stroma  consisting  of  spindle  cells  or  ﬁbroblasts  with  a  brisk  mitotic  activ-
ity. The  malignant  spindle  cell  proliferation  showed  positive  staining  with  p-53  and  a  high
proliferation  index  with  ki-67.  A  diagnosis  of  AFS  was  rendered.
Conclusion:  The  differential  diagnosis  includes  other  odontogenic  sarcomas,  ameloblastic  car-
cinosarcoma  and  spindle  cell  carcinoma.  Treatment  of  choice  is  wide  surgical  excision,  with
long-term  follow-up.  Postoperative  chemotherapy  and  radiotherapy  has  been  used  successfully
in a  few  reported  cases.  AFS  is  a  locally  aggressive  malignant  tumor,  with  regional  and  distant
metastases  being  uncommon.
© 2013  Elsevier  Masson  SAS.  All  rights  reserved.
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sIntroduction
Ameloblastic  ﬁbrosarcoma  (AFS)  is  an  extremely  rare  malig-
nant  odontogenic  tumor  that  was  ﬁrst  described  in  1887  [1].
To  the  best  of  our  knowledge  only  71  cases  of  AFS  have  been
reported  in  the  literature  with  most  cases  occurring  in  the
mandible  within  the  third  decade  of  life.∗ Corresponding author. Tel.: +1 313 609 7302;
fax: +1 313 881 4727.
E-mail address: magilani@hotmail.com (S.M. Gilani).
A
w
o
s
a
b
m
1879-7296/$ – see front matter © 2013 Elsevier Masson SAS. All rights re
http://dx.doi.org/10.1016/j.anorl.2013.03.001ase Report
e  reported  a  rare  case  of  AFS  in  a  16-year-old  female,
ho  presented  with  a month  history  of  right  mandibular
ass,  resulting  in  difﬁculty  in  swallowing.  The  patient  was
orked  up  and  a  maxillofacial  CT-scan  was  performed.  CT
can  showed  a destructive  5-cm  mass  on  the  right  molars.
dditionally,  it  showed  cortical  expansion  and  perforation
ith  invasion  into  pterygopalatine  space  causing  destruction
f  facial  bones  (Fig.  1).  An  incisional  biopsy  was  done.  Micro-
copically,  there  was  a  biphasic  pattern  composed  of  bland
ppearing  epithelium  that  resembled  ameloblastic  ﬁbroma,
ut  quantitatively  less,  along  with  a  malignant  mesenchy-
al  component  (Fig.  2A).  The  mesenchymal  cells  showed
served.
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Figure  1  Computed  Tomography  (CT)  scan  showing  a  mass
lesion straddles  the  right  mandibular  ramus  and  extends  later-
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positivity  for  p53  in  the  sarcomatous  component  along  with
F
Elly and  medially  from  the  right  mandibular  ramus  causing  bony
estruction.
arked  cellularity,  nuclear  atypia  and  occasional  mitoses
Fig.  2B).  The  benign  epithelial  component  showed  uniform
ositivity  for  pan-cytokeratin  (Fig.  3A),  while  the  malignant
esenchymal  component  was  positive  for  p53  (Fig.  3B)  with
 high  proliferation  index  for  Ki67  (Fig.  3C),  while  negative
or  c-KIT  (CD-117)  (Fig.  3D).  Based  on  the  morphology  and
mmunohistochemical  staining  pattern,  a  diagnosis  of  AFS
as  rendered.
iscussionFS  is  a  rare  neoplasm,  in  which  the  clinical  and  patho-
ogical  distinction  from  other  neoplasms  is  essential  for
p
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igure  2  A.  Biphasic  pattern  with  benign  odontogenic  epithelium
 ×  100).  B.  Malignant  proliferation  of  mesenchymal  component  withS.M.  Gilani  et  al.
ppropriate  care.  The  terms  ameloblastic  dentinosarcoma
nd  ameloblastic  odontosarcoma  have  been  used  in  the  past
or  these  types  of  neoplasms  depending  on  the  presence  of
entin  or  enamel  as  some  authors  consider  these  lesions  as
istological  variants  of  the  same  neoplasm.  However,  in  the
ecent  World  Health  Organization  (WHO)  ‘‘classiﬁcation’’
f  odontogenic  tumors,  ameloblastic  odontosarcoma  and
entinosarcoma  are  listed  separately  from  AFS.  AFS  occurs
ithin  a  wide  age  range  from  3  to  89  years  [2].
The  mean  age  at  time  of  presentation  for  all  reported
ases  is  27.3  years  [3].  Of  the  62  cases  analyzed  by  Huguet
t  al.,  20  arose  in  previously  benign  AFS  [4].
The  usual  clinical  presentation  consists  of  a patient  who
omplains  of  a  painful  but  occasionally  painless,  facial  mass
ith  accompanying  paresthesia  or  dysesthesia.  The  duration
f  symptoms  varies  widely  from  a  few  weeks  up  to  2  years.
Radiologically,  AFS  presents  as  destructive  expansile  radi-
lucent  mass  with  irregular  and  ill-deﬁned  borders.  Grossly
he  tumor  may  be  cystic  or  solid  with  a  ﬂeshy  whitish  to  yel-
ow  consistency  that  usually  causes  destruction  the  bone.
he  epithelial  component  is  present  in  the  form  of  nests  and
ranching  cords  with  anastomosing  strands  of  odontogenic
pithelium  exhibiting  peripheral  palisading  that  resembles
he  developing  enamel  organ.  The  mesenchymal  cells  vary
rom  hyperchromatic  spindle  to  stellate  that  exhibit  mod-
rate  to  marked  nuclear  pleomorphism  with  a  high  number
f  mitotic  ﬁgures.  Dentin  matrix  material  may  be  present
ithin  the  intercellular  areas.  Ultrastructually,  these  tumors
xhibit  features  of  ﬁbroblasts.
The  sarcomatous  mesenchymal  component  of  AFS  is  pos-
tive  for  p53  and  proliferating  cell  nuclear  antigen  (PCNA)
s  compared  to  negativity  for  these  stains  in  AF  [4].  The
esenchymal  component  of  recurrent  AF  and  AFS  usually
how  higher  labeling  indices  for  Ki-67  as  compared  with  non-
ecurrent  AF  [5].  Williams  et  al.  identiﬁed  diffuse  nuclearositivity  for  c-KIT  (CD  117)  [6].  However,  expression  of
D-117  is  variable  in  AFS  and  can  show  a  negative  stain-
ng  pattern.  Pontes  and  coworkers  demonstrated  a  positive
 surrounded  by  hypercellular  mesenchymal  component  (H  &
 mitosis  (H  &  E  ×  400).
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Figure  3  A.  Cytokeratin  AE1/AE3  expression  in  benign  epithelial  component  (×  100).  B.  Positive  expression  for  p53  in  sarcomatous
wing
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cstromal component  (×  100).  C.  Ki-67  expression  in  the  tumor  sho
epithelial and  mesenchymal  component  (×  100).
BCL-2  expression  within  the  sarcomatous  portion  of  the
tumor,  while  negative  in  the  epithelial  component  [7].  This
staining  pattern  is  the  opposite  in  AF.
The  differential  diagnosis  includes  other  odontogenic
sarcomas,  speciﬁcally  two  closely  related  entities  that
have  similar  histological  features  as  AFS,  ameloblastic
ﬁbrodentinosarcoma  and  ﬁbro-odontosarcoma  (Table  1).
These  sarcomas  have  similar  morphologic  features  of
AFS;  however,  in  addition  they  either  have  dysplastic
dentin  (ﬁbro-dentinosarcoma)  and/or  enamel  and  dentin
h
n
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Table  1  Differential  diagnosis  of  Ameloblastic  ﬁbrosarcoma  (AFS
Differential  diagnosis  Morphologic  features
Ameloblastic  ﬁbrosarcoma  The  bland  epithelial  
hypercellular  maligna
staining  for  p53  prote
Ameloblastic  ﬁbroma  Immature  mesenchym
component.  Less  cell
Ameloblastic  ﬁbro-odontoma  Histological  appearan
teeth  are  present
Fibrodentinosarcoma  Mixed  epithelial  and  
tissue
Fibro-odontosarcoma  Resemble  AFS  but  the
scattered  throughout
Ameloblastic  carcinosarcoma  Ameloblastic  atypica
malignant  mesenchym
Spindle-cell  carcinoma  Malignant  appearanc
carcinoma high  proliferation  index  (×  100).  D.  CD-117  is  negative  in  both
ﬁbro-odontosarcoma)  [2]  a  feature  not  seen  in  AFS.
eanwhile,  ameloblastic  carcinosarcoma,  another  entity
ithin  the  differential  diagnosis,  shows  a  malignant  spin-
le  cell  proliferation  along  with  carcinomatous  elements.
n  comparison,  AFS  does  not  have  a  malignant  epithelial
omponent.  Additionally,  spindle  cell  carcinoma  can  also  be
onfused  with  AFS.  However,  the  neoplasm  has  a  biphasic
istological  picture,  consisting  of  a  squamous  cell  carci-
oma  and  a  malignant  spindle  cell  lesion.  As  a  minority  of
FS  arise  from  a  pre-existing  AF,  this  remains  an  important
).
component  is  present  in  a  branching  cord  pattern  with  a
nt  mesenchymal  or  ﬁbroblastic  component.  Usually  positive
in  with  high  proliferation  index  for  Ki-67
al  tissue  consisting  of  ﬁbroblasts  admixed  with  epithelial
ular,  absent  mitotic  activity  and  benign  stromal  component
ce  similar  to  ameloblastic  ﬁbroma;  however,  well-formed
mesenchymal  tissue,  similar  to  AFS  with  dysplastic  dentin
y  have  hard  dental  tissue  including  dysplastic  enamel
l  cells,  with  high  mitotic  index  and  necrosis.  Admixed  with
al  spindle  cell  component
e  of  spindle  cell  lesion  with  features  of  squamous  cell
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ifferential  diagnosis.  Microscopically  AF  is  composed  of
trands  and  islands  of  ameloblastic  epithelium  embedded
ithin  a  pulp  like,  myxoid  cellular  connective  tissue,  which
esembles  odontogenic  mesenchyme.  Special  attention
hould  be  given  to  the  stroma,  which  is  characteristically
alignant  in  AFS.
The  treatment  modalities  for  AFS  include  a  combination
f  chemotherapy,  radiotherapy  accompanied  with  wide  sur-
ical  resection  of  the  affected  segment  of  the  maxilla  or
andible  with  long-term  follow-up.  Combination  or  adju-
ant  chemotherapy  is  regarded  as  having  provided  complete
emission  in  one  of  the  reported  cases,  which  had  an  exten-
ive  maxillary  lesion  [8].  The  chemotherapeutic  regimes
sed  in  that  case  include  daily  oral  cyclophosphamide,
eekly  intravenous  actinomycin-D  and  vincristine.  Also  post-
perative  radiotherapy  (50  Gy)  has  been  used  successfully.
abolinejad  et  al.  recommend  adding  radiation  to  the  treat-
ent  for  the  prevention  of  recurrence  especially  in  cases
f  incomplete  surgical  resection  [1].  Demoor-Goldschmidt
t  al.  reported  two  pediatric  cases  with  AFS  and  suggested
he  effectiveness  of  combination  of  chemotherapy,  radio-
herapy  with  wide  surgical  excision  and  follow-up  [9].  AFS  is
onsidered  a  locally  aggressive  neoplasm  with  a  low  poten-
ial  for  distant  metastasis  (4.5%)  and  having  overall  mortality
ate  of  25.4%.  Thirty-seven  percent  of  the  reported  cases  of
FS  showed  at  least  one  recurrence  [8].  The  patients  with
FS  have  a  better  prognosis  with  this  form  of  sarcoma  than
ther  tumors  of  the  jaw  [10].
onclusion
FS  is  an  extremely  rare  odontogenic  tumor  with  unclear
tiology,  which  has  clinical  and  radiological  features  similar
o  other  odontogenic  tumors.  The  rarity  of  these  neoplasms
lus  their  overlapping  features  with  other  odontogenic
umors  can  make  diagnosis  challenging.  These  cases  should
e  discussed  and  reviewed  by  oral  pathologists  in  multidisci-
linary  conferences,  dealing  with  sarcoma,  at  national  and
nternational  level.
[S.M.  Gilani  et  al.
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